Buyer Protection 60-Day Moneyback Guarantee Shop with confidence
Typical dosing: 48mg taken 30 minutes before meals or as needed for breakthrough nausea
Poster Session I - NOVEL TARGET/ EXPERIMENTAL FIDINGS TO CLINICAL TRANSLATION 06.00 - NOVEL TARGET/ EXPERIMENTAL FIDINGS TO CLINICAL TRANSLATION - 06.02 - GENETICS, OMICS AND BIOMARKERS P451 - ESOC25-1378 GENETIC INSIGHTS INTO PROTECTIVE EFFECTS OF GLP-1 RECEPTOR AGONISTS ON STROKE AND ALZHEIMERS DISEASE RISK IN EUROPEAN AND EAST-ASIAN POPULATIONS Ilana Caro 1 , Muralidharan Sargurupremraj 2 , David-Alexandre Trgout 3 , Daichi Shigemizu 4,5 , Thierry Couffinhal 6,7 , Yoichiro Kamatani 8 , Kamel Mohammedi 6,9 , Stphanie Debette 3,10 1 Bordeaux Population Health research center, Inserm, UMR U1219, Universit de Bordeaux, Bordeaux, France, 2 Glenn Biggs Institute for Alzheimers and Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio, United States, 3 Bordeaux Population Health research center - Universit de Bordeaux, Bordeaux, France, 4 Medical Genome Center, National Center for Geriatrics and Gerontology, Aichi, Japan, 5 Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan, 6 Inserm, Biologie Des Maladies Cardiovasculaires, U1034, Universit de Bordeaux, Bordeaux, France, 7 Department of Cardiology, CHU de Bordeaux, Bordeaux, Bordeaux, France, 8 Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan, 9 Department of Endocrinology, Diabetology and Nutrition, CHU de Bordeaux, Bordeaux, France, 10 Department of Neurology, Institute for Neurodegenerative Diseases, CMRR, CHU de Bordeaux, Bordeaux, France Background and Aims: Stroke and dementia are leading causes of death and disability worldwide requiring enhanced preventive strategies
& Brown, J
Benedikt Frank: Nothing to disclose
